Nuvectis Pharma, Inc. (NASDAQ: NVCT) has priced its previously announced underwritten public offering of 5 million shares of common stock at $20.00 per share, with expected gross proceeds of approximately $100 million. The company has also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the same price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions.
The proceeds from this offering are intended to advance the development of Nuvectis's key pipeline programs: NXP100, NXP200, and NXP900. Additionally, the funds will support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes. Cantor is serving as the sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners acting as co-managers.
Nuvectis Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune complement-related conditions and oncology. Its pipeline includes NXP100, a complement Factor B inhibitor for complement-mediated diseases; NXP900, an oral small molecule inhibitor of the SRC Family of Kinases; and NXP200, an oral, brain-penetrant BRAF inhibitor for various solid tumors. The company believes these candidates have best-in-class potential in their respective areas.
The successful completion of this offering is a significant milestone for Nuvectis, providing the capital necessary to progress its promising therapies through clinical development. For more information, visit the company's website at https://nuvectis.com/.
